Lexology December 20, 2023
Phillips Lytle LLP

MAPS PBC Submission for Approval of MDMA Is a First for Psychedelic-Assisted Therapy

On December 12, 2023, the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS PBC) announced their submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for MDMA (midomafetamine) in combination with psychotherapy for the treatment of post-traumatic stress disorder (PTSD).1 This marks the first NDA submission for any psychedelic-assisted therapy and is a major milestone for the medicinal psychedelics industry.

MDMA, often grouped in the category of psychedelics, is a synthetic psychoactive compound classified as an entactogen — meaning it induces emotional states such as openness and oneness. Mental health professionals were already using MDMA in combination with psychotherapy to...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
MHE Week in Review – New PBM Reform Bill, Cardiac Diseases Cost
Deep learning uncovers gene targets and potential drugs to slow brain aging
FDA issues flu vaccine recommendations: 5 respiratory updates
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
HIMSSCast: The 'genetic revolution' is underway

Share This Article